WO2013009790A3 - A heat stable oxygen carrier-containing pharmaceutical composition for different treatment applications - Google Patents

A heat stable oxygen carrier-containing pharmaceutical composition for different treatment applications Download PDF

Info

Publication number
WO2013009790A3
WO2013009790A3 PCT/US2012/046130 US2012046130W WO2013009790A3 WO 2013009790 A3 WO2013009790 A3 WO 2013009790A3 US 2012046130 W US2012046130 W US 2012046130W WO 2013009790 A3 WO2013009790 A3 WO 2013009790A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
hemoglobin
tetrameric hemoglobin
heat stable
linked
Prior art date
Application number
PCT/US2012/046130
Other languages
French (fr)
Other versions
WO2013009790A2 (en
Inventor
Bing Lou Wong
Sui Yi Kwok
Sze Hang Lau
Original Assignee
Bing Lou Wong
Sui Yi Kwok
Sze Hang Lau
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47506871&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2013009790(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to JP2014520266A priority Critical patent/JP6100252B2/en
Priority to CN201280034336.9A priority patent/CN103687609B/en
Priority to KR1020147003393A priority patent/KR101925346B1/en
Priority to AP2014007422A priority patent/AP3840A/en
Priority to CA2841445A priority patent/CA2841445C/en
Priority to NZ619782A priority patent/NZ619782B2/en
Priority to EP12811843.7A priority patent/EP2731619A4/en
Priority to AU2012282692A priority patent/AU2012282692B2/en
Priority to EA201400020A priority patent/EA201400020A1/en
Priority to BR112014000535A priority patent/BR112014000535A2/en
Application filed by Bing Lou Wong, Sui Yi Kwok, Sze Hang Lau filed Critical Bing Lou Wong
Priority to MX2014000355A priority patent/MX346736B/en
Publication of WO2013009790A2 publication Critical patent/WO2013009790A2/en
Publication of WO2013009790A3 publication Critical patent/WO2013009790A3/en
Priority to MA36701A priority patent/MA35279B1/en
Priority to ZA2014/00698A priority patent/ZA201400698B/en
Priority to HK14104507.2A priority patent/HK1192714A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

A highly purified and heat stable cross-linked nonpolymeric tetrameric hemoglobin suitable for use in mammals without causing renal injury and vasoconstriction is provided. A high temperature and short time (HTST) heat processing step is performed to remove undesired dimeric form of hemoglobin, uncross-linked tetrameric hemoglobin, and plasma protein impurities effectively. Addition of N-acetyl cysteine after heat treatment and optionally before heat treatment maintains a low level of met-hemoglobin. The heat stable cross-linked tetrameric hemoglobin can improve and prolong oxygenation in normal and hypoxic tissue. In another aspect, the product is used in the treatment of various types of cancer such as leukemia, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal carcinoma and esophageal cancer. The inventive tetrameric hemoglobin can also be used to prevent tumor metastasis and recurrence following surgical tumor excision. Further the inventive tetrameric hemoglobin can be administered to patients prior to chemotherapy and radiation treatment.
PCT/US2012/046130 2011-07-11 2012-07-11 A heat stable oxygen carrier-containing pharmaceutical composition for different treatment applications WO2013009790A2 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
MX2014000355A MX346736B (en) 2011-07-11 2012-07-11 A heat stable oxygen carrier-containing pharmaceutical composition for different treatment applications.
BR112014000535A BR112014000535A2 (en) 2011-07-11 2012-07-11 PHARMACEUTICAL COMPOSITION CONTAINING THERMALLY STABLE OXYGEN CARRIER FOR APPLICATIONS IN DIFFERENT TREATMENTS
EA201400020A EA201400020A1 (en) 2011-07-11 2012-07-11 PHARMACEUTICAL COMPOSITION CONTAINING A HEAT-RESISTANT OXYGEN TRANSFER FOR VARIOUS APPLICATIONS IN MEDICAL TREATMENTS
AP2014007422A AP3840A (en) 2011-07-11 2012-07-11 A heat stable oxygen carrier-containing pharmaceutical composition for different treatment applications
CN201280034336.9A CN103687609B (en) 2011-07-11 2012-07-11 The pharmaceutical composition containing the thermally-stabilised carrier of oxygen for different treatment use
NZ619782A NZ619782B2 (en) 2011-07-11 2012-07-11 A heat stable oxygen carrier-containing pharmaceutical composition for different treatment applications
EP12811843.7A EP2731619A4 (en) 2011-07-11 2012-07-11 A heat stable oxygen carrier-containing pharmaceutical composition for different treatment applications
JP2014520266A JP6100252B2 (en) 2011-07-11 2012-07-11 Pharmaceutical composition containing a thermostable oxygen carrier for different therapeutic uses
KR1020147003393A KR101925346B1 (en) 2011-07-11 2012-07-11 A heat stable oxygen carrier-containing pharmaceutical composition for different treatment applications
CA2841445A CA2841445C (en) 2011-07-11 2012-07-11 A heat stable oxygen carrier-containing pharmaceutical composition for different treatment applications
AU2012282692A AU2012282692B2 (en) 2011-07-11 2012-07-11 A heat stable oxygen carrier-containing pharmaceutical composition for different treatment applications
MA36701A MA35279B1 (en) 2011-07-11 2014-01-21 Pharmaceutical composition containing a thermostable oxygen carrier for different treatment applications
ZA2014/00698A ZA201400698B (en) 2011-07-11 2014-01-29 A heat stable oxygen carrier-containing pharmaceutical composition for different treatment applications
HK14104507.2A HK1192714A1 (en) 2011-07-11 2014-05-13 A heat stable oxygen carrier-containing pharmaceutical composition for different treatment applications

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/179,590 2011-07-11
US13/179,590 US8048856B1 (en) 2010-06-23 2011-07-11 Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition

Publications (2)

Publication Number Publication Date
WO2013009790A2 WO2013009790A2 (en) 2013-01-17
WO2013009790A3 true WO2013009790A3 (en) 2013-04-04

Family

ID=47506871

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/046130 WO2013009790A2 (en) 2011-07-11 2012-07-11 A heat stable oxygen carrier-containing pharmaceutical composition for different treatment applications

Country Status (17)

Country Link
US (1) US8048856B1 (en)
EP (1) EP2731619A4 (en)
JP (1) JP6100252B2 (en)
KR (1) KR101925346B1 (en)
CN (1) CN103687609B (en)
AP (1) AP3840A (en)
AU (1) AU2012282692B2 (en)
BR (1) BR112014000535A2 (en)
CA (1) CA2841445C (en)
CL (1) CL2014000053A1 (en)
EA (1) EA201400020A1 (en)
HK (1) HK1192714A1 (en)
MA (1) MA35279B1 (en)
MX (1) MX346736B (en)
MY (1) MY169908A (en)
WO (1) WO2013009790A2 (en)
ZA (1) ZA201400698B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201400206WA (en) 2011-09-06 2014-03-28 Bing Lou Wong Oral delivery for hemoglobin based oxygen carriers
US20140106004A1 (en) * 2012-10-12 2014-04-17 Bing Lou Wong Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence
US9636404B2 (en) * 2013-05-13 2017-05-02 Vision Global Holdings Ltd. Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging
US9225652B2 (en) * 2013-12-05 2015-12-29 Huawei Technologies Co., Ltd. Framework for traffic engineering in software defined networking
US9814759B2 (en) 2014-07-02 2017-11-14 Cheer Global Ltd. Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment
US9763889B2 (en) 2015-06-29 2017-09-19 Billion King International Ltd. Oral delivery system for hemoglobin based oxygen carriers
US10052290B2 (en) 2016-02-04 2018-08-21 Billion King International Ltd. Enteric-coated hemoglobin multiparticulate for oral delivery of hemoglobin based oxygen carriers

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5387672A (en) * 1993-03-02 1995-02-07 The University Of Maryland At Baltimore Hemoglobin intramolecularly cross-linked withlong chain divalent reagents
US6956025B2 (en) * 2000-06-29 2005-10-18 Sanguibiotech Gmbh Mammalian haemoglobin compatible with blood plasma, cross-linked and conjugated with polyalkylene oxides as artificial medical oxygen carriers, production and use thereof
US7932356B1 (en) * 2010-06-23 2011-04-26 Bing Lou Wong Method for the preparation of a heat stable oxygen carrier-containing pharmaceutical composition

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2548671B1 (en) 1983-07-07 1986-05-02 Merieux Inst PROCESS FOR THE PREPARATION OF A GLOBIN FROM HEMOGLOBIN AND A GLOBIN OBTAINED BY THIS PROCESS
US4831012A (en) 1984-03-23 1989-05-16 Baxter International Inc. Purified hemoglobin solutions and method for making same
US4600531A (en) 1984-06-27 1986-07-15 University Of Iowa Research Foundation Production of alpha-alpha cross-linked hemoglobins in high yield
US4598064A (en) 1984-06-27 1986-07-01 University Of Iowa Research Foundation Alpha-alpha cross-linked hemoglobins
USRE34271E (en) 1984-06-27 1993-06-01 University Of Iowa Research Foundation Production of alpha-alpha cross-linked hemoglobins in high yield
JPH0750329B2 (en) 1986-06-23 1995-05-31 富士写真フイルム株式会社 Image forming material
US5753616A (en) 1986-11-10 1998-05-19 Biopure Corporation Method for producing a stable polymerized hemoglobin blood-substitute
US5955581A (en) 1986-11-10 1999-09-21 Biopure Corporation Method for producing a stable polymerized hemoglobin blood-substitute
US5084558A (en) 1987-10-13 1992-01-28 Biopure Corporation Extra pure semi-synthetic blood substitute
CA1312009C (en) 1986-11-10 1992-12-29 Carl W. Rausch Extra pure semi-synthetic blood substitute
US5189146A (en) 1987-05-05 1993-02-23 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Pasteurizable, freeze-driable hemoglobin-based blood substitute
US5439882A (en) 1989-12-29 1995-08-08 Texas Tech University Health Sciences Center Blood substitute
US5344393A (en) 1992-02-28 1994-09-06 Alliance Pharmaceutical Corp. Use of synthetic oxygen carriers to facilitate oxygen delivery
US6187744B1 (en) 1992-03-11 2001-02-13 Michael W. Rooney Methods and compositions for regulating the intravascular flow and oxygenating activity of hemoglobin in a human or animal subject
US5840851A (en) 1993-07-23 1998-11-24 Plomer; J. Jeffrey Purification of hemoglobin
US5824781A (en) 1993-08-16 1998-10-20 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5767089A (en) 1993-08-16 1998-06-16 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
TW381022B (en) 1993-08-16 2000-02-01 Hsia Jen Chang Compositions and methods utilizing nitroxides to avoid oxygen toxicity, particularly in stabilized, polymerized, conjugated, or encapsulated hemoglobin used as a red cell substitute
US5817632A (en) 1993-08-16 1998-10-06 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5804561A (en) 1993-08-16 1998-09-08 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5807831A (en) 1993-08-16 1998-09-15 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5741893A (en) 1993-08-16 1998-04-21 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5725839A (en) 1993-08-16 1998-03-10 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules for ERI or MRI
US5840701A (en) 1993-08-16 1998-11-24 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US6242417B1 (en) 1994-03-08 2001-06-05 Somatogen, Inc. Stabilized compositions containing hemoglobin
US5631219A (en) 1994-03-08 1997-05-20 Somatogen, Inc. Method of stimulating hematopoiesis with hemoglobin
WO1995031727A1 (en) 1994-05-13 1995-11-23 Therasorb Medizinische Systeme Gmbh Sterile and pyrogen-free columns coupled to protein for binding and removal of substances from blood
SE9500724D0 (en) 1994-06-23 1995-02-24 Pharmacia Ab Filtration
US6288027B1 (en) 1995-03-23 2001-09-11 Biopure Corporation Preserving a hemoglobin blood substitute with a transparent overwrap
US5895810A (en) 1995-03-23 1999-04-20 Biopure Corporation Stable polymerized hemoglobin and use thereof
US6610832B1 (en) 1995-03-23 2003-08-26 Biopure Corporation Preserving a hemoglobin blood substitute with a transparent overwrap
US5691453A (en) 1995-06-07 1997-11-25 Biopure Corporation Separation of polymerized hemoglobin from unpolymerized hemoglobin on hydroxyapatite using HPLC
US5865784A (en) 1995-06-07 1999-02-02 Alliance Pharmaceutical Corp. Method of hemodilution facilitated by monitoring oxygenation status
JP2000502058A (en) 1995-11-30 2000-02-22 ソマトジェン，インコーポレイテッド Methods for controlling functionality during hemoglobin crosslinking
EP0892830B1 (en) 1996-03-21 2003-08-13 Kobusch-Sengewald GmbH & Co.KG Multilayered sheet, process for the production thereof and use thereof
DE69733664T3 (en) 1996-04-19 2011-04-14 Grifols Inc. (n.d. Ges.d.Staates Delaware), Los Angeles Method of inactivating viruses and lyophilizing blood proteins
US6054427A (en) 1997-02-28 2000-04-25 The Regents Of The University Of California Methods and compositions for optimization of oxygen transport by cell-free systems
US5814601A (en) 1997-02-28 1998-09-29 The Regents Of The University Of California Methods and compositions for optimization of oxygen transport by cell-free systems
AU745209B2 (en) 1998-01-06 2002-03-14 Cerus Corporation Methods for quenching pathogen inactivators in biological materials
US6977140B1 (en) 1998-09-29 2005-12-20 Organ Recovery Systems, Inc. Method for maintaining and/or restoring viability of organs
US6894150B1 (en) 1999-10-01 2005-05-17 Ross Walden Tye Non-pyrogenic, endotoxin-free, stroma-free tetrameric hemoglobin
US6747132B2 (en) 2000-11-29 2004-06-08 Apex Biosciences, Inc. Methods for the synthesis of a modified hemoglobin solution
JP4260417B2 (en) 2001-05-23 2009-04-30 ノバルティス アクチエンゲゼルシャフト System and method for transporting and deoxygenating solutions
US7038016B2 (en) 2001-08-21 2006-05-02 Apex Bioscience, Inc. Methods for purification of an activated PEG solution and for the synthesis of a modified hemoglobin solution
US20050164915A1 (en) 2002-04-01 2005-07-28 Sangart, Inc. Compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
US20030153491A1 (en) 2002-01-11 2003-08-14 Winslow Robert M. Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
ES2360215T3 (en) 2002-12-23 2011-06-01 Albert Einstein College Of Medicine Of Yeshiva University HEMOGLOBINS PEGILATED NON HYPERTENSIVE AND ITS PREPARATION PROCEDURES.
CN100431602C (en) 2003-01-29 2008-11-12 北原实验室有限公司 Polymerized hemoglobin solutions having reduced amounts of tetramer and method for preparing
BRPI0518198B8 (en) 2004-10-29 2021-06-22 Cerus Corp ex vivo method of treating a red cell composition to inactivate a pathogen, if present, as well as composition and kit
US7759306B2 (en) 2006-05-16 2010-07-20 Simoni Jan S Methods of treating acute blood loss
US7504377B2 (en) 2006-10-23 2009-03-17 Ikor, Inc. Nitric oxide-blocked cross-linked tetrameric hemoglobin
US7494974B2 (en) 2006-10-24 2009-02-24 Ikor, Inc. Carboxymethylated cross-linked tetrameric hemoglobin
AU2008266938A1 (en) 2007-06-13 2008-12-24 Opk Biotech Llc Targeted oxygen delivery via intravenous or intra-arterial infusion of oxygenated polymerized hemoglobin solutions
US7989593B1 (en) * 2010-05-27 2011-08-02 Bing Lou Wong Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof
US20110319332A1 (en) * 2010-06-23 2011-12-29 Bing Lou Wong Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5387672A (en) * 1993-03-02 1995-02-07 The University Of Maryland At Baltimore Hemoglobin intramolecularly cross-linked withlong chain divalent reagents
US6956025B2 (en) * 2000-06-29 2005-10-18 Sanguibiotech Gmbh Mammalian haemoglobin compatible with blood plasma, cross-linked and conjugated with polyalkylene oxides as artificial medical oxygen carriers, production and use thereof
US7932356B1 (en) * 2010-06-23 2011-04-26 Bing Lou Wong Method for the preparation of a heat stable oxygen carrier-containing pharmaceutical composition

Also Published As

Publication number Publication date
JP6100252B2 (en) 2017-03-22
ZA201400698B (en) 2015-09-30
KR101925346B1 (en) 2018-12-05
KR20140054038A (en) 2014-05-08
CN103687609B (en) 2016-07-20
EP2731619A2 (en) 2014-05-21
BR112014000535A2 (en) 2017-10-03
HK1192714A1 (en) 2014-08-29
JP2014520850A (en) 2014-08-25
WO2013009790A2 (en) 2013-01-17
EA201400020A1 (en) 2014-06-30
NZ619782A (en) 2016-09-30
MX2014000355A (en) 2015-01-27
CA2841445C (en) 2019-02-26
AP2014007422A0 (en) 2014-02-28
CA2841445A1 (en) 2013-01-17
CL2014000053A1 (en) 2014-08-29
US8048856B1 (en) 2011-11-01
MY169908A (en) 2019-06-14
CN103687609A (en) 2014-03-26
AP3840A (en) 2016-09-30
AU2012282692A1 (en) 2014-01-30
MA35279B1 (en) 2014-07-03
AU2012282692B2 (en) 2017-04-27
MX346736B (en) 2017-03-30
EP2731619A4 (en) 2015-03-11

Similar Documents

Publication Publication Date Title
WO2011162863A8 (en) A method for the preparation of a heat stable oxygen carrier-containing pharmaceutical composition
MY155598A (en) A method for the preparation of a heat stable oxygen carrier-containing pharmaceutical composition
WO2013009790A3 (en) A heat stable oxygen carrier-containing pharmaceutical composition for different treatment applications
NZ594915A (en) A method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof
MX2016007311A (en) Methods for treating cancers.
MX359989B (en) Antiviral drugs for treatment of arenavirus infection.
WO2014186301A8 (en) Pharmaceutical composition comprising modified hemoglobin- based therapeutic agent for cancer targeting treatment and diagnostic imaging
TW201613589A (en) Combination methods for treating cancers
MX2010002278A (en) Antiviral drugs for treatment of arenavirus infection.
MY163300A (en) Method for the preparation of a heat stable oxygen carrier-containing composition facilitating beta-beta cross-linking
MD20160016A2 (en) Novel indolizine derivatives, method for the production thereof and pharmaceutical compositions containing same
JP2015534946A5 (en)
MX2011011525A (en) Stabilized lipid formulation of apoptosis promoter.
TH77663B (en) Method for the preparation of thermally stable oxygen carrier pharmaceutical compositions.
TH122386A (en) Method for the preparation of thermally stable oxygen carrier pharmaceutical compositions.
EA201500579A1 (en) COMBINED THERAPY WITH THE USE OF VOLASERTIBA
TH122386B (en) Method for the preparation of thermally stable oxygen carrier pharmaceutical compositions.
Kitano Combination Therapy of Immune Checkpoint Inhibitors
TH171862A (en) Pharmaceutical constituents with thermally stable oxygen carriers For different therapeutic applications
WO2008106606A3 (en) Carotenoid analogs and derivatives in the treatment of prostate cancer
WO2012142687A8 (en) Antitumour testosterone-(radioactive iodine) compound

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12811843

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2014520266

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: P26/2014

Country of ref document: AE

Ref document number: MX/A/2014/000355

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2841445

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 201400020

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2012282692

Country of ref document: AU

Date of ref document: 20120711

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2012811843

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20147003393

Country of ref document: KR

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014000535

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112014000535

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20140109